Evidence map›Paper›PMID 40672513›Full record

ArticlemedRxiv : the preprint server for health sciences2025

Relationship between BrainAge Polygenetic Risk Score and plasma biomarkers in the A4/LEARN studies.

Jorge Garcia Condado, Mabel Seto, Madison Cuppels, Colin Birkenbihl, Hannah M Klinger, Gillian T Coughlan, Michael J Properzi, Hyun-Sik Yang, Aaron P Schultz, Jasmeer Chhatwal and 7 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Jorge Garcia CondadoComputational Neuroimaging Lab, BioBizkaia Health Research Institute, Barakaldo, Spain.ORCID 0000-0002-9463-1924
Mabel SetoMassachusetts General Hospital, Harvard Medical School, Boston MA, USA.ORCID 0000-0001-8567-2532
Madison CuppelsMassachusetts General Hospital, Harvard Medical School, Boston MA, USA.
Colin BirkenbihlMassachusetts General Hospital, Harvard Medical School, Boston MA, USA.ORCID 0000-0002-7212-7700
Hannah M KlingerMassachusetts General Hospital, Harvard Medical School, Boston MA, USA.
Gillian T CoughlanMassachusetts General Hospital, Harvard Medical School, Boston MA, USA.ORCID 0000-0003-1806-702X
Michael J ProperziMassachusetts General Hospital, Harvard Medical School, Boston MA, USA.
Hyun-Sik YangCenter for Alzheimer Research and Treatment (CART), Brigham and Women's Hospital, Harvard Medical School, Boston MA, USA.ORCID 0000-0002-8318-0443
Aaron P SchultzMassachusetts General Hospital, Harvard Medical School, Boston MA, USA.
Jasmeer ChhatwalMassachusetts General Hospital, Harvard Medical School, Boston MA, USA.ORCID 0000-0002-7792-1698
Dorene M RentzCenter for Alzheimer Research and Treatment (CART), Brigham and Women's Hospital, Harvard Medical School, Boston MA, USA.ORCID 0000-0002-6318-9213
Asier ErramuzpeComputational Neuroimaging Lab, BioBizkaia Health Research Institute, Barakaldo, Spain.ORCID 0000-0002-9402-2184
Jesus M CortesComputational Neuroimaging Lab, BioBizkaia Health Research Institute, Barakaldo, Spain.ORCID 0000-0002-9059-8194
Keith A JohnsonMassachusetts General Hospital, Harvard Medical School, Boston MA, USA.
Reisa A SperlingCenter for Alzheimer Research and Treatment (CART), Brigham and Women's Hospital, Harvard Medical School, Boston MA, USA.ORCID 0000-0003-1535-6133
Rachel F BuckleyMassachusetts General Hospital, Harvard Medical School, Boston MA, USA.ORCID 0000-0002-5356-5537
Ibai DiezComputational Neuroimaging Lab, BioBizkaia Health Research Institute, Barakaldo, Spain.ORCID 0000-0001-5769-0178

Funding

RECRUITMENT COREU19AG010483 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI FELDMAN, HOWARD · 2013 to 2020
$80.6M
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Open-Label Extension StudyR01AG063689 · NIA · BRIGHAM AND WOMEN'S HOSPITAL · PI AISEN, PAUL S., SPERLING, REISA A. · 2019 to 2024
$30.8M
Building predictive algorithms to identify resilience and resistance to Alzheimer's diseaseR01AG079142 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI Rachel Frances Buckley, Michael C Donohue · 2023 to 2026
$4.0M
The inactive X: discovering sex genes that influence female vulnerability to Alzheimer's diseaseDP2AG082342 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI Rachel Frances Buckley · 2022 to 2026
$2.5M
Menopause, hormone therapy and Alzheimer's disease clinicopathology: An in vivo perspectiveK99AG083063 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI COUGHLAN, GILLIAN THERESA · 2024 to 2025
$269k
NIA NIH HHS DP2 AG082342NIA NIH HHS K99 AG083063NIA NIH HHS R01 AG063689NIA NIH HHS R01 AG079142NIA NIH HHS U19 AG010483
6 · The paper itself

Abstract

Background and Objectives: To examine the association between genetic predisposition to accelerated brain aging-measured with polygenic risk scores (PRS) derived from BrainAge models-and plasma biomarkers of Alzheimer's disease (AD), with attention to age and sex-specific effects. Methods: We analyzed 1994 cognitively unimpaired participants from the A4/LEARN studies (71.5±4.8 years; 41% male). We computed the genetic risk of accelerated grey matter loss associated with age using GWAS data from previous studies. Baseline plasma biomarkers included pTau Results: BrainAge PRS moderated the association between age and pTau Discussion: Genetic risk for accelerated grey matter loss with aging is associated with elevated pTau

Identifiers

PMID40672513
PMCPMC12265747

What OpenQuestion holds

Textmetadata
LicenceCC BY-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.